Evidence map›Paper›PMID 41671458›Full record

ArticleJournal of the National Comprehensive Cancer Network : JNCCN2025

Efficacy and Safety of Continuing Next-Generation ALK TKIs With Chemotherapy for Advanced ALK-Positive NSCLC: A Multicenter Retrospective Study.

Sarah Waliany, Shambo Guha Roy, Federica Pecci, Urs M Weber, Fangdi Sun, Zhaohui Arter, Meghanne Lomibao, Joao V Alessi, Mizuki Nishino, Faustine Luo and 16 more

Abstract readMulticenter Study
In one paragraph

Article in Journal of the National Comprehensive Cancer Network : JNCCN, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Sarah Waliany1Massachusetts General Hospital Cancer Center, Massachusetts General Hospital, Boston, MA.
Shambo Guha Roy2Department of Radiology, Massachusetts General Hospital, Boston, MA.
Federica Pecci3Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA.
Urs M Weber4Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, CO.
Fangdi Sun5Division of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford, CA.
Zhaohui Arter6Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, CA.
Meghanne Lomibao7Memorial Sloan Kettering Cancer Center, New York, NY.
Joao V Alessi3Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA.
Mizuki Nishino9Department of Radiology, Center for Pulmonary Functional Imaging, Brigham and Women's Hospital, Boston, MA.
Faustine Luo6Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, CA.
Matteo Repetto7Memorial Sloan Kettering Cancer Center, New York, NY.
Christina Falcon7Memorial Sloan Kettering Cancer Center, New York, NY.
Andrew Do1Massachusetts General Hospital Cancer Center, Massachusetts General Hospital, Boston, MA.
Jennifer Peterson1Massachusetts General Hospital Cancer Center, Massachusetts General Hospital, Boston, MA.
Joyce Liang1Massachusetts General Hospital Cancer Center, Massachusetts General Hospital, Boston, MA.
Audrey Liu1Massachusetts General Hospital Cancer Center, Massachusetts General Hospital, Boston, MA.
Misako Nagasaka6Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, CA.
Biagio Ricciuti3Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA.
Alexander Drilon7Memorial Sloan Kettering Cancer Center, New York, NY.
S Ignatius Ou6Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, CA.
Joel W Neal5Division of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford, CA.
Tejas Patil4Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, CO.
Mark Awad3Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA.
Beow Y Yeap1Massachusetts General Hospital Cancer Center, Massachusetts General Hospital, Boston, MA.
Subba R Digumarthy2Department of Radiology, Massachusetts General Hospital, Boston, MA.
Jessica J Lin1Massachusetts General Hospital Cancer Center, Massachusetts General Hospital, Boston, MA.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Overcoming Resistance Mechanisms to Anaplastic Lymphoma Kinase InhibitorsR01CA164273 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI Aaron N Hata, Jessica Jiyeong Lin · 2012 to 2026
$5.5M
NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA164273
6 · The paper itself

Abstract

backgroundNext-generation ALK tyrosine kinase inhibitors (TKIs; eg, alectinib, brigatinib, ceritinib, ensartinib, lorlatinib) are established first-line therapies for patients with ALK fusion-positive (ALK+) advanced/metastatic non-small cell lung cancer (NSCLC). Chemotherapy-with platinum/pemetrexed (PT/Pem) as the preferred regimen-is considered standard next-line therapy. However, limited data exist on outcomes of continuing next-generation ALK TKIs with subsequent PT/Pem after progression on TKI monotherapy. PATIENTS AND

methodsThis multicentered, retrospective study included patients with ALK+ metastatic NSCLC who received PT/Pem alone or with alectinib or lorlatinib (PT/Pem/TKI) after progression on next-generation ALK TKIs. Endpoints included progression-free survival (PFS), overall survival (OS), 12-month cumulative incidence of intracranial progression, and treatment-related adverse events (trAEs).

resultsWe identified 156 patients, of whom 86 received PT/Pem and 70 received PT/Pem/TKI (alectinib: n=23; lorlatinib: n=47). Median PFS was numerically longer with PT/Pem/TKI versus PT/Pem (6.0 vs 3.5 months; hazard ratio [HR], 0.75; P=.11). In 78 patients treated with the current paradigm of first-line next-generation ALK TKIs, PT/Pem/TKI was associated with longer median PFS (6.6 vs 3.5 months; HR, 0.58; P=.042) and longer median OS (16.4 vs 11.4 months; HR, 0.55; P=.041) than PT/Pem alone. Among patients evaluable for intracranial outcomes (n=98), treatment with PT/Pem/TKI was associated with a significantly lower cumulative incidence of intracranial progression compared with PT/Pem alone (18.7% vs 34.0% at 12 months; HR, 0.33; P=.009). In the safety cohort (n=116), grade ≥3 trAEs occurred in 19 of 62 (30.6%) patients treated with PT/Pem, 5 of 18 (27.8%) patients treated with PT/Pem/alectinib, and 18 of 36 (50.0%) patients treated with PT/Pem/lorlatinib. There were no unanticipated safety signals in patients treated with PT/Pem plus alectinib or lorlatinib.

conclusionsAmong patients who received next-generation ALK TKIs as first-line therapy, continuation of next-generation ALK TKI with PT/Pem led to longer PFS and OS than PT/Pem alone, with no unanticipated toxicities. The modest efficacy of PT/Pem-based regimens overall underscores the need for more effective therapies for TKI-refractory ALK+ NSCLC.

Indexed as

Anaplastic Lymphoma KinaseAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Non-Small-Cell LungLung NeoplasmsProtein Kinase InhibitorsAdultAgedAminopyridinesFemaleHumansLactamsMaleMiddle AgedPyrazolesRetrospective StudiesTreatment OutcomeALK protein, humanAminopyridinesAnaplastic Lymphoma KinaseLactamslorlatinibProtein Kinase InhibitorsPyrazoles

Identifiers

PMID41671458
PMCPMC13062745

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.